Lipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis. There are no approved pharmacologic therapies to lower ...

The atherogenic lipoprotein(a) (Lp(a)) is significantly increased in patients with kidney disease. Some studies in hemodialysis patients described this increase to be dependent on the genetic ...

April 23, 2012 (Chicago, Illinois) — Apolipoprotein(a) (apo[a]) isoform size is associated with myocardial infarction (MI) after adjustment for lipoprotein(a) (Lp[a]). A study was conducted on an ...

CHICAGO, IL—Manufacturers of an investigational drug that targets lipoprotein(a) say they will move ahead with a pivotal trial following the promising results of a phase II dose-ranging study. The ...

A phase 2 trial showing that the novel antisense agent AKCEA-APO(a)-L Rx dramatically lowers lipoprotein(a) levels in patients with elevated Lp(a) and established cardiovascular disease (CVD) has been ...

Mercodia Apo(a) ELISA, manufactured by Mercodia AB of Uppsala, Sweden, is a solid-phase, two-site enzyme immunoassay kit for the measurement of human apolipoprotein(a) in serum. Apolipoprotein(a) is a ...

Lp(a) lipoprotein binds proinflammatory oxidized phospholipids. We investigated whether levels of oxidized low-density lipoprotein (LDL) measured with use of monoclonal antibody E06 reflect the ...